National Politics
On Selma's 50th anniversary, Obama will look to the future

Topics

Drug Research
Amgen says a study found its cancer drug more effective than rival drug
Amgen says a study found its cancer drug more effective than rival drug

Amgen Inc., the Thousand Oaks biotech giant, said Sunday a new study has found its cancer drug Kyprolis is far more effective in treatment of relapsed multiple myeloma than its chief rival. The study found that patients treated with Kyprolis after a second onset of multiple myeloma lived twice as long without the disease progressing as those treated with Velcade, a drug marketed by Johnson & Johnson and Takeda Pharmaceutical Co., Amgen said in a news release. “It’s a very big deal,” said Sean E. Harper, executive vice president of research and development for Amgen. “Velcade is an enormous, blockbuster product. It’s the only drug in its class. And now...

Loading